Impression

Topics

• Biomarkers
• Antibody-based therapeutics
• The Central Nervous System
• From Academia to big Pharma

Speakers

• B. van der Baan - VP Commercial Operations - Agendia BV
  

• dr.ir. P.A.W. van den Berg - Head of Research & Business Services - LURIS
  

• dr. K. Bol - Director Project Management - Kinesis Pharma BV
  

• H. Breek - CEO - Cavadis
  

• prof.dr. M.J.A.P. Daemen - Co-founder - ACS Biomarkers

• A. Dijkstra PhD - Chief Business Officer - PanGenetics BV
  

• S. van den Eijnde - Director Business Development - MUbio Products BV
  

• R. van der Geest PhD - Chief Development Officer - Kinesis Pharma BV
  

• prof.dr. F. Grosveld - Professor Dept of Cell Biology - ErasmusMC
  

• C. Kruse - Solvay Pharmaceuticals
  

• J.W. de Leeuw - Senior Manager consultancy services - LURIS
  

• drs. J. van der Leijé - CEO - Biqualys, The Advanced Analysis Company
  

• P. Leufkens - CEO - Neurophyxia B.V.
  

• drs. A.C.M. van der Linden RA - Partner - PWC Accountants N.V.
  

• dr. T. Logtenberg - CEO - Merus BV
  

• ir. M. Loos - Research Scientist - Synaptologics BV
  

• prof. W.J. Niessen PhD - Prof. Medical Informatics & Radiology - ErasmusMC
  

• dr. W.J. van Oort - CEO - AIMM Therapeutics BV
  

• P. Parren - Sr. VP Research & Pre-Clinical Development - Genmab

• dr.ing. K. Recourt - Investment Manager - Stichting Mibiton
  

• drs. P.M. Slijkerman - General Manager - ZF-screens BV

• T. Trimborn PhD - CEO - Therosteon

• G. Zondag - Director Technology - DNage B.V.
   

Participants

• Over 250 participants
• 93 dedicated Life Sciences companies
• 14 academic medical centres and universities
• 32 consultancy companies (law, finance, business development and marketing)
• 20 investors and Life Sciences funds
• 18 governmental and branch organisations
• 25 tabletops

Investors forum